Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free TLSA Stock Alerts

Tiziana Life Sciences (TLSA) Financials

Tiziana Life Sciences logo
$1.26 +0.01 (+0.80%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$1.25 -0.01 (-0.40%)
As of 07/9/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Tiziana Life Sciences

Annual Income Statements for Tiziana Life Sciences

This table shows Tiziana Life Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.12 -8.53 -7.96 -9.32 -26 -28 -19 -16 -12 -19
Consolidated Net Income / (Loss)		 -9.77 -8.59 -7.93 -9.32 -26 -23 -15 -18 -12 -18
Net Income / (Loss) Continuing Operations		 -9.77 -8.59 -7.93 -9.32 -26 -37 -15 -18 -12 -19
Total Pre-Tax Income 		-9.89 -11 -9.88 -10 -28 -27 -15 -17 -17 -18
Total Operating Income		 -9.88 -10 -9.87 -9.92 -28 -27 -15 -18 -16 -21
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 -13 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 13 0.00 0.00 0.00 0.00
Total Operating Expenses		 9.88 10 9.87 9.92 28 27 15 18 16 21
Research & Development Expense		 4.01 6.02 5.51 3.71 5.99 13 13 8.11 5.23 10
Other Operating Expenses / (Income)		 - 4.48 4.36 6.21 22 14 1.63 9.87 11 11
Total Other Income / (Expense), net		 -0.01 -0.01 -0.01 -0.09 -0.31 0.72 -0.81 0.74 -0.95 2.70
Other Income / (Expense), net		 -0.01 - - - -0.31 0.72 -0.81 0.74 -0.95 2.33
Income Tax Expense		 -0.12 -1.91 -1.95 -0.69 -2.21 -3.24 0.00 0.45 -4.88 0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 -0.65 - - - - 4.48 3.58 -1.49 0.07 0.09
Basic Earnings per Share		 ($0.11) ($0.09) ($0.06) - ($0.16) ($0.24) ($0.15) ($0.17) ($0.11) ($0.16)
Weighted Average Basic Shares Outstanding		 - - 136.46M 136.65M 194.61M 102.27M 102.27M 103.09M 111.46M 120.51M
Diluted Earnings per Share		 ($0.11) ($0.09) - - ($0.16) ($0.24) ($0.15) ($0.17) ($0.11) ($0.16)
Weighted Average Diluted Shares Outstanding		 - - 136.46M 136.65M 194.61M 102.27M 102.27M 103.09M 111.46M 120.51M
Basic & Diluted Earnings per Share		 ($0.11) ($0.09) - - ($0.16) ($0.24) ($0.15) ($0.17) ($0.11) ($0.16)
Weighted Average Basic & Diluted Shares Outstanding		 - - 136.46M 136.65M 194.61M 102.27M 102.27M 103.09M 111.46M 120.51M

Quarterly Income Statements for Tiziana Life Sciences

No quarterly income statements for Tiziana Life Sciences are available.

Annual Cash Flow Statements for Tiziana Life Sciences

This table details how cash moves in and out of Tiziana Life Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -5.69 -5.99 13 -5.12 64 5.67 -6.98 0.51 17 16
Net Cash From Operating Activities		 -8.61 -7.53 3.40 -6.80 -5.82 5.69 -5.66 0.60 13 5.74
Net Cash From Continuing Operating Activities		 -8.61 -7.63 3.40 -8.56 -5.82 5.69 -5.66 0.60 13 5.74
Net Income / (Loss) Continuing Operations		 -9.89 -11 0.00 -10 0.00 0.00 0.00 0.00 0.00 0.00
Depreciation Expense		 0.01 0.01 0.02 0.01 0.09 0.14 0.05 0.10 0.12 0.23
Non-Cash Adjustments To Reconcile Net Income		 1.27 0.56 3.24 0.45 -6.94 4.87 -7.07 0.51 12 4.97
Changes in Operating Assets and Liabilities, net		 0.00 2.30 0.14 1.00 1.03 0.69 1.36 0.00 0.00 0.53
Net Cash From Investing Activities		 -0.34 -0.00 0.00 -0.00 0.00 -0.15 0.00 0.00 -0.02 -0.02
Net Cash From Continuing Investing Activities		 -0.05 -0.00 0.00 -0.00 0.00 -0.15 0.00 0.00 -0.02 -0.02
Purchase of Property, Plant & Equipment		 -0.05 -0.00 - -0.00 - - - 0.00 -0.02 -0.02
Net Cash From Financing Activities		 1.58 1.54 10 1.68 76 0.13 -1.32 -0.09 4.59 10
Net Cash From Continuing Financing Activities		 1.58 1.54 10 1.88 76 0.13 -1.32 -0.09 4.59 10
Repurchase of Common Equity		 - - - - 0.00 0.00 -1.32 -0.25 -0.05 0.00
Issuance of Debt		 0.96 0.00 1.51 1.88 4.47 0.13 0.00 0.00 4.45 0.00
Issuance of Common Equity		 0.61 1.54 8.58 - 71 0.00 0.00 0.16 0.12 10
Other Financing Activities, net		 - - - - - - - 0.00 0.08 0.10

Quarterly Cash Flow Statements for Tiziana Life Sciences

No quarterly cash flow statements for Tiziana Life Sciences are available.

Annual Balance Sheets for Tiziana Life Sciences

This table presents Tiziana Life Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2.47 6.92 2.38 71 49 26 12 11 11
Total Current Assets		 2.45 6.91 1.36 70 49 24 7.34 7.51 8.55
Cash & Equivalents		 0.06 5.30 0.20 66 42 18 1.18 3.72 4.01
Accounts Receivable		 2.38 1.61 1.16 4.20 6.49 6.16 6.15 3.78 4.54
Plant, Property, & Equipment, net		 0.02 0.01 0.01 0.00 0.02 0.02 0.01 0.02 0.03
Total Noncurrent Assets		 0.00 0.00 1.01 0.63 0.13 0.37 4.84 3.76 2.92
Other Noncurrent Operating Assets		 - 0.00 0.72 0.36 0.00 0.37 4.84 3.76 2.92
Total Liabilities & Shareholders' Equity		 2.47 6.92 2.38 71 49 26 12 11 11
Total Liabilities		 4.75 6.40 7.89 8.27 7.55 6.91 6.65 7.35 11
Total Current Liabilities		 4.75 6.40 7.27 7.90 7.54 6.65 6.54 7.34 11
Accounts Payable		 4.75 6.40 6.99 7.31 7.54 6.53 6.39 7.23 10
Other Current Liabilities		 - - 0.28 0.59 0.00 0.12 0.15 0.11 0.22
Total Noncurrent Liabilities		 0.00 0.00 1.98 0.38 0.01 0.24 0.11 0.00 0.76
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - 0.00 0.53
Other Noncurrent Operating Liabilities		 - 0.00 0.62 0.38 0.01 0.24 0.11 0.00 0.23
Total Equity & Noncontrolling Interests		 -2.28 0.52 -6.87 62 41 20 5.54 3.94 0.05
Total Preferred & Common Equity		 -2.28 0.52 -6.87 62 41 20 5.54 3.94 0.05
Total Common Equity		 -2.28 0.52 -6.87 62 41 20 5.54 3.94 0.05
Common Stock		 8.14 8.59 8.60 0.10 0.10 0.10 0.10 0.11 0.12
Retained Earnings		 -43 -51 -60 -85 -108 -116 -134 -145 -163
Other Equity Adjustments		 32 43 45 147 149 137 141 149 163

Quarterly Balance Sheets for Tiziana Life Sciences

No quarterly balance sheets for Tiziana Life Sciences are available.

Annual Metrics And Ratios for Tiziana Life Sciences

This table displays calculated financial ratios and metrics derived from Tiziana Life Sciences' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 136,463,818.00 136,654,516.00 194,612,289.00 102,272,614.00 204,545,228.00 103,087,744.00 103,087,744.00 103,087,744.00
DEI Adjusted Shares Outstanding		 0.00 0.00 682,319,090.00 341,636,290.00 194,612,289.00 102,272,614.00 204,545,228.00 103,087,744.00 103,087,744.00 103,087,744.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.01 -0.03 -0.13 -0.27 -0.09 -0.16 -0.12 -0.18
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -6.07% 6.00% -0.66% -184.86% 6.13% 42.13% -11.73% 3.06% -11.68%
EBIT Growth		 0.00% -6.09% 5.97% -0.55% -185.64% 5.93% 42.24% -11.98% 2.88% -12.25%
NOPAT Growth		 0.00% -6.22% 5.97% -0.55% -182.49% 2.33% 46.72% -23.30% 12.18% -33.80%
Net Income Growth		 0.00% 12.05% 7.67% -17.51% -180.29% 10.39% 34.25% -14.90% 32.94% -55.37%
EPS Growth		 0.00% 12.05% 0.00% 0.00% 0.00% -50.00% 37.50% -13.33% 35.29% -45.45%
Operating Cash Flow Growth		 0.00% 12.52% 145.16% -299.76% 14.36% 197.80% -199.47% 110.63% 1,978.90% -54.15%
Free Cash Flow Firm Growth		 0.00% 0.00% 10.78% -34.76% -263.95% 0.92% 50.36% -60.56% 59.94% -53.14%
Invested Capital Growth		 0.00% 0.00% -104.31% -19.41% 39.83% 73.65% 61.59% 1,350.86% -94.85% -1,868.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 98.78% 81.80% 80.31% 93.12% 92.21% 87.85% 100.00% 102.60% 70.84% 100.00%
Interest Burden Percent		 100.00% 100.11% 100.12% 100.92% 100.00% 100.00% 100.00% 100.00% 100.00% 98.05%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 377.22% 902.10% 293.55% -94.14% -45.18% -50.61% -140.92% -250.49% -924.32%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -397.19% -302.68% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 377.22% 902.10% 293.55% -94.14% -45.18% -50.61% -140.92% -250.49% -924.32%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 377.22% -1,528.71% 135.69% -41.89% -56.73% -78.67% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.92 -7.35 -6.91 -6.94 -20 -19 -10 -13 -11 -15
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -3,899.69% -38.27% -114.70% -20.14% -7.88% -16.70% -48.36% -32.98% -94.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -52.17% -227.40% -280.89% -28,446.92%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -9.89 -10 -9.87 -9.92 -28 -27 -15 -17 -17 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.88 -10 -9.85 -9.92 -28 -27 -15 -17 -17 -19
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.27 0.00 11.06 4.53 3.13 10.35 18.23 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 1.27 0.00 11.08 4.54 3.13 10.35 18.23 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12.89 303.78 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 25.41 0.00 93.17 5.44 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 -0.20 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 -0.20 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 0.03 3.05 0.65 -1.16 -1.04 -1.02 -0.84 -0.52 -1.94
Leverage Ratio		 0.00 -1.08 -5.34 -1.46 1.32 1.15 1.24 1.54 2.48 5.71
Compound Leverage Factor		 0.00 -1.09 -5.35 -1.48 1.32 1.15 1.24 1.54 2.48 5.60
Debt to Total Capital		 0.00% 0.00% 0.00% -24.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% -24.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 124.61% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.14 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -0.12 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.14 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.20 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -0.17 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.20 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -38.72 -14.82 3.93 48.12 10.97 -1.95 -14.78 -16.99 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.52 1.08 0.19 8.87 6.46 3.65 1.12 1.02 0.80
Quick Ratio		 0.00 0.52 1.08 0.19 8.87 6.46 3.65 1.12 1.02 0.80
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -5.00 -4.46 -6.02 -22 -22 -11 -17 -6.93 -11
Operating Cash Flow to CapEx		 -17,939.58% -753,300.00% 0.00% -169,900.00% 0.00% 0.00% 0.00% 0.00% 65,868.42% 27,323.81%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 1.79 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 203.49 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -2.34 -4.79 -5.71 -3.44 -0.91 -0.35 4.35 0.22 -3.96
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.34 -2.44 -0.93 2.28 2.53 0.56 4.70 -4.13 -4.19
Enterprise Value (EV)		 0.00 4.32 -4.64 738 624 145 43 56 68 0.00
Market Capitalization		 4.38 4.38 0.66 737 690 187 61 57 72 0.00
Book Value per Share		 $0.00 ($5.14) $0.00 ($0.05) $0.46 $0.21 $0.19 $0.05 $0.04 $0.00
Tangible Book Value per Share		 $0.00 ($5.14) $0.00 ($0.05) $0.46 $0.21 $0.19 $0.05 $0.04 $0.00
Total Capital		 0.00 -2.28 0.52 -5.51 62 41 20 5.54 3.94 0.05
Total Debt		 0.00 0.00 0.00 1.36 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 1.36 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -0.06 -5.30 1.16 -66 -42 -18 -1.18 -3.72 -4.01
Capital Expenditures (CapEx)		 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.37 -4.79 -6.11 -3.70 -1.04 -0.49 -0.39 -3.55 -6.14
Debt-free Net Working Capital (DFNWC)		 0.00 -2.30 0.51 -5.91 62 41 18 0.80 0.17 -2.13
Net Working Capital (NWC)		 0.00 -2.30 0.51 -5.91 62 41 18 0.80 0.17 -2.13
Net Nonoperating Expense (NNE)		 2.85 1.25 1.03 2.38 6.51 4.26 5.19 5.10 0.81 3.64
Net Nonoperating Obligations (NNO)		 0.00 -0.06 -5.30 1.16 -66 -42 -20 -1.18 -3.71 -4.01
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.02 0.01 0.09 0.14 0.05 0.10 0.12 0.23
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($0.01) ($0.03) ($15.46) $0.00 $0.00 ($0.17) $0.00 ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 682.32M 341.64M 194.61M 102.27M 0.00 103.09M 0.00 120.51M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($0.01) ($0.03) ($15.46) $0.00 $0.00 ($0.17) $0.00 ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 682.32M 341.64M 194.61M 102.27M 0.00 103.09M 0.00 120.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($0.01) ($0.03) ($15.46) $0.00 $0.00 ($0.17) $0.00 ($0.16)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 682.32M 341.64M 194.61M 102.27M 0.00 103.09M 0.00 120.51M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.92 -7.35 -6.91 -6.94 -19 -19 -10 -13 -11 -15
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8.57% -1.43% -0.44% 0.00%

Quarterly Metrics And Ratios for Tiziana Life Sciences

No quarterly metrics and ratios for Tiziana Life Sciences are available.


Financials Breakdown Chart

Tiziana Life Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tiziana Life Sciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Tiziana Life Sciences' net income appears to be on an upward trend, with a most recent value of -$18.43 million in 2025, rising from -$9.77 million in 2016. The previous period was -$11.86 million in 2024. See where experts think Tiziana Life Sciences is headed by visiting Tiziana Life Sciences' forecast page.

Tiziana Life Sciences' total operating income in 2025 was -$21.13 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $21.13 million

Over the last 9 years, Tiziana Life Sciences' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

Tiziana Life Sciences' total liabilities were at $11.44 million at the end of 2025, a 55.7% increase from 2024, and a 141.0% increase since 2017.

In the past 8 years, Tiziana Life Sciences' cash and equivalents has ranged from $64 thousand in 2017 to $65.82 million in 2020, and is currently $4.01 million as of their latest financial filing in 2025.

Over the last 9 years, Tiziana Life Sciences' book value per share changed from 0.00 in 2016 to 0.00 in 2025, a change of 0.0%.


Related Companies

Financial statements for NASDAQ:TLSA last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
The tiny chipmaker set to supply Musk 5 billion chips
SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsof...
Brownstone Research | Sponsoredtc pixel
The market’s crashing? … There’s an app for that
During the Great Financial Crisis, one firm accurately predicted 464 of 465 bank failures before they happened...
Weiss Ratings | Sponsoredtc pixel